Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Disopyramide is an effective inhibitor of mutant HERG K+ channels involved in variant 1 short QT syndrome.

Journal of molecular and cellular cardiology - 1 Sept 2006

McPate Mark J, Duncan Rona S, Witchel Harry J, Hancox Jules C

Abstract excerpt

The recently identified idiopathic short QT syndrome (SQTS) is associated with an increased risk of arrhythmia and sudden death. The use of implantable cardioverter defibrillators helps to protect SQTS patients from ventricular fibrillation; however, pharmacological treatments to normalise the QT interval are limited: thus far only quinidine has been found to be effective in a subset of patients, with the SQT1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Arrhythmia Agents
Share to Arrhythmias, Cardiac

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cricetulus

Share to Death, Sudden, Cardiac

Share to Electrophysiology

Share to ERG1 Potassium Channel

Share to Ether-A-Go-Go Potassium Channels

Share to Potassium Channels

Source

Identifiers

PMID: 16842817
DOI: 10.1016/j.yjmcc.2006.05.021

Genes

KCNH2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Disopyramide is an effective inhibitor of mutant HERG K+ channels involved in variant 1 short QT syndrome.PMID 16842817Read ↗

Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs.Semantic proximity Read ↗

In vivo effects of mutant HERG K+ channel inhibition by disopyramide in patients with a short QT-1 syndrome: a pilot study.Semantic proximity Read ↗

Emerging therapeutic targets in the short QT syndrome.Semantic proximity Read ↗

In silico assessment of the effects of quinidine, disopyramide and E-4031 on short QT syndrome variant 1 in the human ventricles.Semantic proximity Read ↗

Action potential clamp and pharmacology of the variant 1 Short QT Syndrome T618I hERG K⁺ channel.Semantic proximity Read ↗

Molecular determinants of hERG potassium channel inhibition by disopyramide.Semantic proximity Read ↗

Drug-induced torsades de pointes: the evolving role of pharmacogenetics.Semantic proximity Read ↗

Stereoselective block of the hERG potassium channel by the Class Ia antiarrhythmic drug disopyramide.Semantic proximity Read ↗

hERG potassium channels and cardiac arrhythmia.Semantic proximity Read ↗

[Short QT syndrome].Semantic proximity Read ↗

Acquired QT interval prolongation and HERG: implications for drug discovery and development.Semantic proximity Read ↗

A novel mutation in the KCNH2 gene associated with short QT syndrome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.